Glucocorticoids (GCs) are the most effective and commonly used drugs for the treatment of systemic lupus erythematosus (SLE). However, a large number of side effects occur after long-term or high-dose glucocorticoid treatment, which severely restricts the use of glucocorticoids. Reconstituted high-density lipoprotein (rHDL), an emerging nanocarrier, is promising for targeted delivery to sites of inflammation and macrophages. Here, we prepared a steroid-loaded recombinant high-density lipoprotein and evaluated its therapeutic efficacy in a murine macrophage cell line (RAW264.7) and a lupus (MRL/lpr mice) mouse model. The obtained corticosteroid-loaded nanomedicine, named PLP-CaP-rHDL, exhibited desirable characteristics. Pharmacodynamics studies revealed that the nanoparticles could significantly reduce the levels of inflammatory cytokines in the macrophages in vitro and also effectively alleviate lupus nephritis in MRL/lpr mice without causing obvious side effects at a dose of 0.25 mg/kg. Thus, our newly developed steroid-loaded rHDL nanocarriers hold a great potential for anti-inflammatory therapy with reduced side effects and may provide a precise targeted therapy for SLE.
GottschalkTATsantikosEHibbsML. Pathogenic inflammation and its therapeutic targeting in systemic lupus erythematosus. Front Immunol2015; 6: 550.
3.
MunozLEJankoCSchulzeC, et al.Autoimmunity and chronic inflammation - two clearance-related steps in the etiopathogenesis of SLE. Autoimmun Rev2010; 10: 38–42.
4.
MohammadiSSaghaeian-JaziMSedighiS, et al.Immunomodulation in systemic lupus erythematosus: induction of M2 population in monocyte-derived macrophages by pioglitazone. Lupus2017; 26: 1318–1327.
5.
IwataYBostromEAMenkeJ, et al.Aberrant macrophages mediate defective kidney repair that triggers nephritis in lupus-susceptible mice. J Immunol2012; 188: 4568–4580.
6.
HutchesonJVanarsaKBashmakovA, et al.Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus. Arthritis Res Ther2012; 14: R243.
7.
MaRJiangWLiZ, et al.Intrarenal macrophage infiltration induced by T cells is associated with podocyte injury in lupus nephritis patients. Lupus2016; 25: 1577–1586.
8.
DurcanLO’DwyerTPetriM. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet2019; 393: 2332–2343.
9.
OzbakirBCrielaardBJMetselaarJM, et al.Liposomal corticosteroids for the treatment of inflammatory disorders and cancer. J Control Release2014; 190: 624–636.
10.
MetselaarJMWaubenMHWagenaar-HilbersJP, et al.Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum2003; 48: 2059–2066.
11.
MetselaarJM. Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Ann Rheum Dis2004; 63: 348–353.
12.
UlmanskyRTurjemanKBaruM, et al.Glucocorticoids in nano-liposomes administered intravenously and subcutaneously to adjuvant arthritis rats are superior to the free drugs in suppressing arthritis and inflammatory cytokines. J Control Release2012; 160: 299–305.
13.
LorscheiderMTsapisNUr-RehmanM, et al.Dexamethasone palmitate nanoparticles: an efficient treatment for rheumatoid arthritis. J Control Release2019; 296: 179–189.
14.
MoallemEKorenEUlmanskyR, et al.A liposomal steroid nano-drug for treating systemic lupus erythematosus. Lupus2016; 25: 1209–1216.
15.
SylvesterBPorfireAMunteanDM, et al.Optimization of prednisolone-loaded long-circulating liposomes via application of quality by design (QbD) approach. J Liposome Res2018; 28: 49–61.
16.
YangMFengXDingJ, et al.Nanotherapeutics relieve rheumatoid arthritis. J Control Release2017; 252: 108–124.
ZannisVIChroniAKriegerM. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med (Berl)2006; 84: 276–294.
19.
HeDZhaoMWuC, et al.Apolipoprotein A-1 mimetic peptide 4F promotes endothelial repairing and compromises reendothelialization impaired by oxidized HDL through SR-B1. Redox Biol2018; 15: 228–242.
20.
SaddarSCarriereVLeeWR, et al.Scavenger receptor class B type I is a plasma membrane cholesterol sensor. Circ Res2013; 112: 140–151.
21.
HuangJLJiangGSongQX, et al.Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis. Nat Commun2017; 8: 15144.
22.
SongQHuangMYaoL, et al.Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer’s disease by accelerating the clearance of amyloid-beta. ACS Nano2014; 8: 2345–2359.
23.
AustinHA,3rdMuenzLRJoyceKM, et al.Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int1984; 25: 689–695.
24.
AndersHJSaxenaRZhaoMH, et al.Lupus nephritis. Nat Rev Dis Primers2020; 6: 7.
25.
JiaMDengCLuoJ, et al.A novel dexamethasone-loaded liposome alleviates rheumatoid arthritis in rats. Int J Pharm2018; 540: 57–64.
26.
Pirmardvand CheginiSVarshosazJTaymouriS. Recent approaches for targeted drug delivery in rheumatoid arthritis diagnosis and treatment. Artif Cells Nanomed Biotechnol2018; 46: 502–514.
27.
SchweingruberNHaineATiedeK, et al.Liposomal encapsulation of glucocorticoids alters their mode of action in the treatment of experimental autoimmune encephalomyelitis. J Immunol2011; 187: 4310–4318.
28.
BartneckMPetersFMWarzechaKT, et al.Liposomal encapsulation of dexamethasone modulates cytotoxicity, inflammatory cytokine response, and migratory properties of primary human macrophages. Nanomedicine2014; 10: 1209–1220.
29.
GraingerDJRecklessJMcKilliginE. Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice. J Immunol2004; 173: 6366–6375.
30.
AliKMiddletonMPureE, et al.Apolipoprotein E suppresses the type I inflammatory response in vivo. Circ Res2005; 97: 922–927.
31.
ChristensenDJOhkuboNOddoJ, et al.Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J Immunol2011; 186: 2535–2542.
32.
BaitschDBockHHEngelT, et al.Apolipoprotein E induces antiinflammatory phenotype in macrophages. Arterioscler Thromb Vasc Biol2011; 31: 1160–1168.
33.
LiKChingDFuSL, et al.Apolipoprotein E enhances microRNA-146a in monocytes and macrophages to suppress nuclear factor-κB–driven inflammation and atherosclerosisnovelty and significance. Circ Res2015; 117: e1–e11.
34.
AlvarezPGenreFIglesiasM, et al.Modulation of autoimmune arthritis severity in mice by apolipoprotein E (ApoE) and cholesterol. Clin Exp Immunol2016; 186: 292–303.
35.
LiJYangYHuangL. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J Control Release2012; 158: 108–114.
36.
GrahamFLVan der EbAJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology1973; 52: 456–467.
37.
KatzerTChavesPBernardiA, et al.Prednisolone-loaded nanocapsules as ocular drug delivery system: development, in vitro drug release and eye toxicity. J Microencapsul2014; 31: 519–528.
38.
HanafyAFAbdallaAMGudaTK, et al.Ocular anti-inflammatory activity of prednisolone acetate loaded chitosan-deoxycholate self-assembled nanoparticles. Int J Nanomed2019; 14: 3679–3689.
39.
VermaAJainATiwariA, et al.Folate conjugated double liposomes bearing prednisolone and methotrexate for targeting rheumatoid arthritis. Pharm Res2019; 36: 123.
40.
KraftJCFreelingJPWangZ, et al.Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci2014; 103: 29–52.
41.
MaedaH. Polymer therapeutics and the EPR effect. J Drug Target2017; 25: 781–785.
42.
NatfjiAARavishankarDOsbornHMI, et al.Parameters affecting the enhanced permeability and retention effect: the need for patient selection. J Pharm Sci2017; 106: 3179–3187.
43.
CormodeDPSkajaaTVan SchooneveldMM, et al.Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett2008; 8: 3715–3723.
44.
ZhouSHuangYChenY, et al.Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy. Biomaterials2020; 235: 235.
45.
FanouriakisAKostopoulouMAlunnoA, et al.2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis2019; 78: 736–745.
46.
BertsiasGIoannidisJPBoletisJ, et al.EULAR recommendations for the management of systemic lupus erythematosus. report of a task force of the EULAR standing committee for international clinical studies including therapeutics. Ann Rheum Dis2008; 67: 195–205.
47.
SmithCKSetoNLVivekanandan-GiriA, et al.Lupus high-density lipoprotein induces proinflammatory responses in macrophages by binding lectin-like oxidised low-density lipoprotein receptor 1 and failing to promote activating transcription factor 3 activity. Ann Rheum Dis2017; 76: 602–611.
48.
RauchhausUSchwaigerFPanznerS. Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: long-term suppression of arthritis facilitates interval treatment. Arthritis Res Ther2009; 11: R190.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
